CSL’s vaccine arm Seqirus has been awarded an advance order contract with the Public Health Agency of Canada to supply 15 ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Dr Michael Wilson, Senior Vice President and Head of Research at CSL; Associate Professor Remy Robert from the Monash Biomedicine Discovery ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

Australian vaccine manufacturer, CSL Seqirus, has been awarded a contract to support the influenza pandemic preparedness plans.

SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization.

Here's what to expect from the Biotech stock next. The post 3 reasons why the CSL share price could leap 87% to $274!

Two of Australia’s corporate heavyweights, CSL (ASX: CSL) and BHP Group (ASX: BHP), released their earnings results today – but the market reaction could not be more different (CSL is getting smashed, ...

Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...